Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2009

View Archived Issues

Kowa claims novel G-protein-coupled receptor 40 and 120 agonists as antidiabetic agents

Novel vanilloid receptor ligands for the treatment of pain disclosed by Amgen

NeuroSearch presents novel potassium channel modulators for the treatment of respiratory disorders

GlaxoSmithKline claims novel compounds for the treatment of anemia

Amgen presents p38 protein kinase inhibitors for the treatment of rheumatoid arthritis

Second-generation FLT3 inhibitor developed as a candidate for acute myeloid leukemia therapy

Preclinical studies of ARRY-520 aid in selecting target cancers

Ajinomoto and Dainippon granted approval for additional indication for Niflec and Gasmotin

AcelRx initiates phase II cancer breakthrough pain program

First-in-man results with IDX-84, data on other HCV treatments from Idenix presented

OPERA-1 interim results show potent antiviral activity of TMC-435 against hepatitis C

Perlegen and Celera sign license agreement for cardiovascular biomarkers

CHMP issues positive opinion for AstraZeneca's oral anticancer drug, Iressa

FDA approves IND for ConjuGon's phase Ib C-1205 trial

Zoledronic acid may reduce androgen-deprivation-induced bone loss in prostate cancer patients

FDA extends review timeline for Onglyza NDA

Promising preclinical results seen with new HCV protease inhibitors EA-058, EA-063

Genesis changes name to Jiangbo Pharmaceuticals

Selective inhibitors of anaplastic lymphoma kinase show in vitro and in vivo antitumor activity

Novo Nordisk receives positive CHMP opinion on Victoza

Nycomed's Instanyl receives positive CHMP opinion for cancer pain

Targacept initiates phase II TC-5214 study in patients with resistant hypertension

Pfizer and University College London to collaborate on stem cell-based therapies for AMD

Health Canada approves Cangene's hepatitis B therapeutic HepaGam B for second indication

Simponi receives FDA approval as once-monthly anti-TNF for RA

Icagen completes enrollment in phase II study of senicapoc in allergic asthma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...